Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharmacol Exp Ther ; 326(1): 41-50, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18434589

RESUMO

The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) (Proc Natl Acad Sci U S A 83:3331-3335, 1986) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degradation in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice (Proc Natl Acad Sci U S A 102:16078, 2005). In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats. GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC(50) value of 0.2 microM. GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-alpha production by 60 to 85%, indicating a duration of action of at least 5 h. In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiology, histology and bone mineral content measurements. In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers. GW2580 administered to normal rats for 21 days showed no effects on tissue histology and only modest changes in serum clinical chemistry and blood hematology. In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.


Assuntos
Anisóis/uso terapêutico , Artrite Experimental/tratamento farmacológico , Artrite Experimental/enzimologia , Inibidores de Proteínas Quinases/uso terapêutico , Pirimidinas/uso terapêutico , Receptor de Fator Estimulador de Colônias de Macrófagos/antagonistas & inibidores , Animais , Anisóis/farmacologia , Artrite Experimental/patologia , Células Cultivadas , Humanos , Masculino , Inibidores de Proteínas Quinases/farmacologia , Pirimidinas/farmacologia , Ratos , Ratos Endogâmicos Lew , Vírus do Sarcoma Felino/efeitos dos fármacos , Vírus do Sarcoma Felino/enzimologia
2.
Chem Biol Interact ; 23(1): 1-11, 1978 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-81113

RESUMO

Human fibroblast cells treated with benzo[alpha]pyrene (BP), aflatoxin B1 (AFB1) or N-acetoxy-2-fluorenylacetamide (A-AAF) inhibited Snyder-Theilen feline sarcoma virus (ST-FeSV) focus formation. Inhibition of focus formation resulting from chemical treatment was not related to cytotoxic concentrations of chemicals in that little or not effect on cells surviving treatment was observed. Maximum inhibition of focus formation occurred with BP when the cells were treated before infection. By contrast, maximum inhibition of focus formation occurred with A-AAF and AFB1 when the cells were treated after virus infection. Inhibition of focus formation by BP and AFB1 was eliminated when virus infected cells were treated 48-96 h post-infection. While no infectious virus was detected in either chemical treated or untreated ST-FeSV virus infected cultures, comparable levels of virus-directed RNA dependent DNA polymerase enzyme assay (RDDP) activity were found in both treated and untreated cultures. The data show that the inhibitory effect on focus formation is chemically mediated while the inhibition of virus synthesis is not.


Assuntos
Carcinógenos/farmacologia , Transformação Celular Viral/efeitos dos fármacos , Retroviridae/efeitos dos fármacos , Vírus do Sarcoma Felino/efeitos dos fármacos , Acetoxiacetilaminofluoreno/farmacologia , Aflatoxinas/farmacologia , Benzopirenos/farmacologia , Células Cultivadas , Humanos , Pirenos/farmacologia , DNA Polimerase Dirigida por RNA/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...